• EZ Cap™ Mouse CD252(OX40L) mRNA: Assay Strategy

  2026-09-15

  Explore how EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) can support mechanistic immune co-stimulation studies. This guide distinguishes OX40L-specific assay design from related mRNA vaccine evidence and translates the literature into practical controls and readouts.

• EGTA and Calcium Flux: From Channel Biology to Translation

  2026-09-15

  EGTA, or egtazic acid, offers translational researchers a practical way to interrogate calcium-dependent injury without confusing calcium availability with channel subtype activity. This article connects calcium chelation to neuroprotection, cardiac vagal physiology, assay design, and more disciplined model selection.

• Fucoidan Workflows for Breast Cancer Research

  2026-09-14

  Build reproducible Fucoidan assays around MCF-7 cytotoxicity, migration, colony formation, and caveolin-1 analysis. This workflow also shows how to connect breast cancer findings with apoptosis, angiogenesis, and immune-modulation studies without overextending the evidence.

• 17-AAG (Tanespimycin): Reliable Cell Assays

  2026-09-14

  A scenario-based guide to improving viability, proliferation, and cytotoxicity experiments with 17-AAG (Tanespimycin), SKU A4054. It connects HSP90 biology with formulation control, dose-response design, endpoint interpretation, and practical product selection for reproducible cancer research.

• GW 4869: Exosome Workflow for Lupus Nephritis

  2026-09-13

  GW 4869 hydrochloride hydrate provides a practical pharmacologic gate for testing whether neutral sphingomyelinase-dependent vesicle release drives endothelial injury. This workflow combines donor-cell perturbation, extracellular vesicle normalization, HMGB1/TRIM27 pathway testing, and controls that distinguish exosome effects from broader sphingolipid signaling.

• Necrostatin 2 (Nec-2) Workflow for Necroptosis

  2026-09-12

  Necrostatin 2 (Nec-2) provides a temporally controlled way to investigate programmed necrotic cell death, RIPK2 signaling, and membrane-injury phenotypes. This practical guide connects Nec-2 dose optimization with the Kupffer-cell and plasma-membrane findings reported in Listeria research, while clearly separating established evidence from exploratory applications.

• Blebbistatin for Causal Cell Mechanics Imaging

  2026-09-11

  Use (±)-Blebbistatin to connect non-muscle myosin II activity with migration, adhesion, and morphology while preserving a reversible live-cell workflow. Inspired by panoramic cardiac mapping, the approach pairs mechanical perturbation with registered structure–function imaging for stronger causal interpretation.

• Neuritin, ER Stress, and NF-κB After SAH

  2026-09-11

  The reference study identifies coordinated endoplasmic reticulum stress pathways as drivers of NF-κB-linked neuroinflammation and neuronal apoptosis during early brain injury after subarachnoid hemorrhage. Its central contribution is showing that neuritin overexpression suppresses these convergent pathways, providing a mechanistic framework for evaluating neuroprotective interventions in SAH.

• Native-Membrane Proteoforms and Drug Selectivity

  2026-09-10

  A 2025 Nature Chemistry study introduces native top-down mass spectrometry for connecting membrane-protein modifications with ligand interactions in intact lipid environments. Using retinal rhodopsin, G proteins, and PDE6, the authors show that proteoform identity and lipidation can shape drug binding and off-target selectivity.

• Native Proteoform Interactions for Drug Targeting

  2026-09-10

  This Nature Chemistry study introduces native top-down mass spectrometry for resolving membrane-protein proteoforms and their ligand interactions without first removing the native lipid environment. Its analysis of rhodopsin, G-protein lipidation, and PDE6 binding by Vardenafil and sildenafil shows why modification-resolved pharmacology can reveal off-target behavior missed by conventional assays.

• Vardenafil HCl Trihydrate in PDE5 Research

  2026-09-09

  Vardenafil HCl Trihydrate gives researchers a high-potency, selective tool for connecting PDE5 inhibition with cGMP signaling, smooth muscle relaxation, and functional erectile dysfunction models. Its use can be extended into proteoform-aware workflows that compare soluble enzyme assays with native membrane and PDE6 counter-screening.

• Sodium Orthovanadate in Translational Signaling

  2026-09-09

  A mechanistic and strategic guide to using Sodium Orthovanadate and Na3VO4 for phosphorylation state preservation, insulin-signaling studies, kinase assays, and translational assay design.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-09-08

  The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that connects protein modification with iron uptake, ferroptosis, and trophoblast syncytialization in preeclampsia. Its combination of O-GlcNAc modification proteomics, mechanistic validation, trophoblast models, and mouse experiments provides a framework for testing how placental stress is regulated.

• Ceftolozane/Tazobactam: Mechanism, Evidence, and Limits

  2026-09-08

  The reference review presents ceftolozane/tazobactam as an engineered antipseudomonal cephalosporin–β-lactamase inhibitor combination designed to preserve activity against important resistant Gram-negative pathogens. Its key practical contribution is linking PBP pharmacology, β-lactamase coverage, pharmacokinetic/pharmacodynamic targets, renal dosing, and clinical-trial evidence into a framework for evaluating resistant-infection therapies.

• Vernakalant Hydrochloride: AF Assay Workflows

  2026-09-07

  Vernakalant Hydrochloride supports translational studies that connect atrial ion-channel pharmacology with rapid conversion of atrial fibrillation. This guide presents exposure-aware cell assays, PK-linked interpretation, workflow controls, and troubleshooting strategies for RSD1235 research.

7941 records 1/530 page Next 12345 下5页 Last page